{"id":110,"kind":"story","title":"KONEXT Secures 15 Billion KRW, Pharmarise Becomes Shareholder","url":"https://www.venturesquare.net/1053968/","host":"venturesquare.net","by":"mrlatte","score":1,"comments":0,"time":"2026-03-16T06:57:14.000Z","origin":"archive","language":{"source":"ko","reading":"en","translated":true},"summary":["Pharmarise joined KONEXT's 15 billion KRW Series C investment as a strategic investor.","For bio founders, the point of interest is securing a partner who can support from clinical trials to commercialization, along with the investment amount.","However, merely participating in the investment does not necessarily accelerate the development schedule; clear agreements on who takes on what tasks and by when are necessary to expect support beyond funding in actual collaboration."],"discussion":"https://startupxo.com/en/110/","markdown":"https://startupxo.com/en/110.md","api":"https://startupxo.com/api/v1/item.json?id=110&lang=en","text":null,"edited":null,"sources":[],"thread":[]}